Catalent, Inc. (NYSE:CTLT) Director Gregory T. Lucier sold 5,068 shares of the stock in a transaction on Tuesday, November 23rd. The shares were sold at an average price of $127.35, for a total value of $645,409.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Catalent stock opened at $129.59 on Thursday. The stock’s fifty day simple moving average is $131.59 and its 200 day simple moving average is $121.17. Catalent, Inc. has a 12 month low of $91.87 and a 12 month high of $142.64. The company has a market capitalization of $22.18 billion, a PE ratio of 40.88, a PEG ratio of 2.18 and a beta of 1.32. The company has a current ratio of 3.59, a quick ratio of 3.02 and a debt-to-equity ratio of 1.05.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, November 1st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.06. Catalent had a return on equity of 14.64% and a net margin of 13.68%. During the same period in the prior year, the business posted $0.33 EPS. Analysts predict that Catalent, Inc. will post 3.46 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Selective Wealth Management Inc. acquired a new stake in shares of Catalent in the 3rd quarter valued at about $27,000. Assetmark Inc. acquired a new stake in shares of Catalent in the 3rd quarter valued at about $34,000. Berman Capital Advisors LLC raised its stake in shares of Catalent by 131.2% in the 2nd quarter. Berman Capital Advisors LLC now owns 326 shares of the company’s stock valued at $35,000 after purchasing an additional 185 shares during the period. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of Catalent in the 3rd quarter valued at about $40,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Catalent in the 2nd quarter valued at about $43,000. 97.63% of the stock is currently owned by hedge funds and other institutional investors.
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Featured Story: What is the Russell 2000 Index?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.